VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
HRMY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HRMYHarmony Biosciences Holdings, Inc.
$33.01$1.9B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. HRMY
  4. Financial Ratios

Harmony Biosciences Holdings, Inc. (HRMY) Financial Ratios

Latest Ratios: P/E Ratio 11.0x · EV/EBITDA 5.7x · ROE 20.8%. (2018–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

HRMY Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Market Cap$1.9B$2.2B$2.0B$2.0B$3.4B$2.5B$2.1B——
Enterprise Value$1.4B$1.7B$1.7B$1.8B$3.3B$2.5B$2.1B——
P/E Ratio →11.0313.8113.7115.1618.5573.52———
P/S Ratio1.932.522.793.357.698.2713.09——
P/B Ratio2.222.523.024.188.3613.5421.52——
P/FCF5.926.309.118.9023.3325.69———
P/OCF5.496.299.068.8923.3025.61———

P/E links to full P/E history page with 30-year chart

HRMY EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
EV / Revenue—1.932.413.157.578.1412.88——
EV / EBITDA5.717.188.008.4723.0823.3775.55——
EV / EBIT6.717.308.229.2926.8440.34———
EV / FCF—4.827.868.3622.9725.30———

HRMY Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Gross Margin77.2%77.2%78.1%79.2%80.9%81.8%82.6%73.7%—
Operating Margin24.0%24.0%26.7%33.0%27.4%28.7%10.6%-2433.8%—
Net Profit Margin18.3%18.3%20.4%22.1%41.4%11.3%-23.1%-2535.1%—

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
ROE20.8%20.8%25.8%29.6%61.6%24.4%-86.3%-434.6%-48.9%
ROA14.0%14.0%16.1%17.4%32.8%8.0%-13.8%-155.1%-44.7%
ROIC42.0%42.0%38.9%41.2%36.2%62.3%20.4%-57.0%—
ROCE22.6%22.6%25.9%30.9%24.7%26.0%9.0%-172.8%-50.5%

HRMY Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Debt / Equity0.280.280.280.410.481.052.00—3.98
Debt / EBITDA1.021.020.840.891.331.847.14——
Net Debt / Equity—-0.59-0.41-0.25-0.13-0.21-0.35—2.95
Net Debt / EBITDA-2.19-2.19-1.26-0.55-0.36-0.36-1.26——
Debt / FCF—-1.47-1.24-0.54-0.36-0.39———
Interest Coverage15.6815.6811.968.306.572.55-0.31-24.03—

Net cash position: cash ($753M) exceeds total debt ($240M)

HRMY Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Current Ratio3.603.603.312.755.075.291.951.5811.99
Quick Ratio3.583.583.272.725.025.211.931.5311.99
Cash Ratio3.083.082.672.164.104.361.701.2311.55
Asset Turnover—0.680.720.720.650.700.370.06—
Inventory Turnover37.0237.0221.7922.6119.4312.537.261.45—
Days Sales Outstanding—40.6842.4046.4945.6341.6450.67259.06—

HRMY Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Dividend Yield—————————
Payout Ratio—————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Earnings Yield9.1%7.2%7.3%6.6%5.4%1.4%———
FCF Yield16.9%15.9%11.0%11.2%4.3%3.9%———
Buyback Yield0.0%0.0%0.0%5.1%0.0%0.0%0.0%——
Total Shareholder Yield0.0%0.0%0.0%5.1%0.0%0.0%0.0%——
Shares Outstanding—$59M$58M$60M$61M$59M$58M$64M$49M

Key Metrics

Growth RegimeDecelerating
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Single-product revenue concentration

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Discount Multiples Reflect Single-Product Risk

Based on reported figures, HRMY trades at a trailing P/E of 12.22 and EV/EBITDA of 6.00, well below peers such as Jazz and Supernus, which carry negative earnings or EBITDA multiples above 24 times.

The compressed trailing multiple suggests the market is pricing HRMY as a mature single-asset business rather than a growth biotech, and the forward P/E of 8.77 implies the market expects earnings to rise meaningfully. Relative to its own history, the stock appears inexpensive on earnings, but the discount may be warranted given that WAKIX still generates the bulk of revenue and year-over-year growth slowed to 12.3% in the latest quarter. Investors should monitor whether the forward earnings expectation holds, since a sustained multiple discount would likely persist until the diversification thesis is demonstrated in reported results.

Margin Compression Outpaces Operating Gains

As reported in the quarterly income data, gross margin fell from 82.7% in 2025Q1 to 70.0% in 2026Q3, while operating margin ranged between 12.4% and 34.2% over the same ten quarters, indicating volatile earning power.

The roughly 13-point gross margin compression appears driven by gross-to-net adjustments and tiered royalty obligations rather than a single event, which suggests pricing pressure may be structural rather than transitory. Operating margin volatility, with R&D rising against a relatively fixed cost base, indicates that operating leverage is not yet consistently flowing to the bottom line. Net margin of 17.9% in the latest quarter should be read against the lumpy quarterly pattern, and investors should treat any single-quarter margin as a weak proxy for normalized earning power.

Returns Decaying Despite Expanding Equity

Based on the ten-quarter ratio series, ROIC declined from a peak of 13.0% in 2025Q3 to 6.9% in 2026Q3, while ROE fell from 8.1% to 4.7% as the equity base grew toward $1.1B.

The decline in ROIC and ROE alongside a growing equity base suggests that incremental capital is being retained in cash and low-return assets, a pattern consistent with a business accumulating liquidity rather than compounding capital. The drop in returns appears driven more by margin compression than by asset efficiency, since asset turnover has remained relatively stable. Investors should watch whether returns recover as margins stabilize, because the current trajectory indicates capital is not yet being deployed at the rates implied by reported profitability.

Working Capital Cycle Tightening Steadily

According to the reported ratio data, the cash conversion cycle compressed from 44 days in 2024Q2 range to 20 days in 2026Q3, driven largely by a longer DPO that rose from 28 days to a peak of 55 days before easing.

The shortening cash conversion cycle suggests improved working capital discipline, though the reliance on supplier payment timing is a meaningful contributor rather than purely operational improvement. DSO remained fairly stable near 0.2 turns of receivables, indicating that customer collection behavior has not been the source of change. Analysts should distinguish between efficiency gains and timing effects, since a reversal in DPO could erase much of the cash benefit.

Minimal Debt With Comfortable Coverage

As reported in the balance sheet data, debt-to-equity fell from 0.35 in 2024Q2 to 0.14 in 2026Q3, and interest coverage stood at 20.36 times in the latest quarter, indicating very low financial risk.

The declining leverage and high coverage ratio suggest debt service poses little strain on reported cash flows, and the balance sheet offers a meaningful buffer should revenue soften. Debt-to-EBITDA of 2.48 is modest, though quarterly EBITDA volatility means the ratio has ranged from 1.62 to 6.90 over the period. Investors may wish to monitor the trajectory, but refinancing risk appears limited based on the reported figures.

Liquidity Buffer Exceeds Operating Needs

Based on reported figures, the current ratio held between 3.13 and 3.84 across all ten quarters, with cash reaching $647.1M in 2026Q3, providing a substantial buffer against near-term obligations.

The consistently high current ratio and quick ratio near 3.4 suggest that short-term liabilities are well covered even without relying on inventory, which is modest given the specialty-pharmacy channel structure. Under a severe revenue shock tied to WAKIX pricing or supply disruption, the cash position would likely sustain operations for an extended period, though the reported figures do not disclose a formal stress scenario. The main consideration is whether this liquidity is being deployed productively, since a large idle cash balance weighs on return metrics.

Peer Multiples Mislead on Single-Asset Business

As reported in the peer data, HRMY's P/E of 12.22 looks cheap against loss-making peers, yet the comparison may overstate value since Jazz and Supernus carry negative earnings that distort multiple-based relative valuation.

Peer multiples with negative denominators are not meaningful, so the apparent discount to Jazz and Supernus reflects measurement limits more than relative cheapness. A more informative lens is cash-adjusted enterprise value against WAKIX-specific gross profit, which would isolate how much of the valuation rests on one product. Investors should weigh the low multiple against unresolved concentration and litigation exposure before treating it as evidence of undervaluation.

Download Financial Ratios Data

Includes 30+ ratios · 8 years · Updated daily

Consensus & Technical Research Suite
Open HRMY Terminal

HRMY Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

HRMY — Frequently Asked Questions

Quick answers to the most common questions about buying HRMY stock.

What is Harmony Biosciences Holdings, Inc.'s P/E ratio?

Harmony Biosciences Holdings, Inc.'s current P/E ratio is 11.0x. The historical average is 27.0x.

What is Harmony Biosciences Holdings, Inc.'s EV/EBITDA?

Harmony Biosciences Holdings, Inc.'s current EV/EBITDA is 5.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 24.3x.

What is Harmony Biosciences Holdings, Inc.'s ROE?

Harmony Biosciences Holdings, Inc.'s return on equity (ROE) is 20.8%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -51.0%.

Is HRMY stock overvalued?

Based on historical data, Harmony Biosciences Holdings, Inc. is trading at a P/E of 11.0x. Compare with industry peers and growth rates for a complete picture.

What are Harmony Biosciences Holdings, Inc.'s profit margins?

Harmony Biosciences Holdings, Inc. has 77.2% gross margin and 24.0% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.

How much debt does Harmony Biosciences Holdings, Inc. have?

Harmony Biosciences Holdings, Inc.'s Debt/EBITDA ratio is 1.0x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.